Skip to main content
. Author manuscript; available in PMC: 2013 Aug 28.
Published in final edited form as: Cancer Res. 2012 Oct 16;72(24):6502–6511. doi: 10.1158/0008-5472.CAN-12-1909

Figure 4.

Figure 4

NEDD9 promotes de novo lung cancer progression of KrasG12D mice. A, pathologic photos of lung tumors from KrasG12D mice at 24 weeks post Lenti-Cre or NEDD9-Cre infection (5 mice per group). Scale bars, 500 μm (top) and 50 μm (bottom). B, statistic analyses of well-or poorly differentiated lung tumors from KrasG12D mice receiving Lenti-Cre or NEDD9-Cre. Data are shown as mean ± SEM. *, P < 0.05 (n = 5). C, Ki-67 immunostaining of lung sections from KrasG12D mice virally infected with either Lenti-Cre or NEDD9-Cre. Scale bars, 50 μm. D, bar diagrams illustrate the percentage of Ki-67–positive staining in lung tumors from KrasG12D mice treated with Lenti-Cre or NEDD9-Cre infection. The percentage of Ki-67 staining was quantified by counting more than 1,000 nuclei staining tumor cells. Data are shown as mean ± SEM. ***, P < 0.001.